deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03582618

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

A Phase 2, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Sponsor: TaiRx, Inc.

Conditions Advanced Cancer Hepatocellular Carcinoma
Interventions CVM-1118 Sorafenib
Updated 15 times since 2018 Last updated: Jan 6, 2023 Started: Jul 12, 2018 Primary completion: Nov 16, 2021 Completion: Dec 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study has been terminated due to slow enrollment

Other Advanced Cancer trials with similar outcome

Browse all Advanced Cancer trials

This PHASE2 trial investigates Advanced Cancer and Hepatocellular Carcinoma and is currently terminated or withdrawn. TaiRx, Inc. leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Mar 2020 · 11 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Dec 2021 · 7 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

15 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Feb 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 10 earlier versions

  1. Feb 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. May 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  5. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  7. Apr 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  8. Jan 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  9. Oct 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  10. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TaiRx, Inc.
Data source: TaiRx, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations